Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472582 | 1.00 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| Acetone SCHEMBL472485 | 0.96 | ADORA1 (0.45) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL13384997 | 0.86 | ADORA1 (0.67) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| Acetone SCHEMBL472483 | 0.77 | AHCY (0.38) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| Acetone SCHEMBL472736 | 0.76 | ADORA1 (0.62) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| Acetone SCHEMBL472703 | 0.75 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL472527 | 0.74 | ADORA1 (0.67) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6397659 | 0.74 | ADORA1 (0.74) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL13384992 | 0.73 | ADORA1 (0.51) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6901588 | 0.67 | DOT1L (0.67) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | disclosed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | disclosed |
| US-7144871-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1476455-A1 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003070739-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.